- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05855707
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis (HAPLO-GEL)
Wharton's Jelly Mesenchymal Stromal Cell (WG-MSC) Injections as GVHD Prophylaxis in Hematopoietic Allogeneic Stem Cell Transplantation With an Haplo-identical Donor : a Dose Escalation Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- With AML/ALL/SMD/SMP or lymphoid neoplasm requiring allogeneic stem cell transplantation
- In complete response (CR) for AML/ALL or CR,partial response (PR) or non pre-treated for SMD/SMP and lymphoid neoplasm
- Without a HLA matched related donor available and with identification of a haploidentical donor (brother, sister, parents, adult children or cousin)
With usual criteria for HSCT:
- ECOG ≤ 2
- No severe and uncontrolled infection
- Cardiac function compatible with high dose of cyclophosphamide
Adequate organ function: ASAT and ALAT ≤ 2N, total bilirubin ≤ 1.5N, creatinine clearance ≥30ml/min (except if those abnormalities are linked to the hematological disease)
Requiring a RIC or non myeloablative conditioning:
(i) >50 years old; (ii) heavily pre-treated; (iii) Comoribidities according to Sorror et al. Blood 2005;106(8):2912-9, notamment HCT/CI≥ 3 (JAMA. 2011 Nov 2;306(17):1874-83).
- With health insurance coverage (bénéficiaire ou ayant droit)
- Understand informed consent or optimal treatment and follow-up
- Contraception methods must be prescribed during all the duration of the research and using effective contraceptive methods during treatment and within 12 months for women of childbearing age and 6 months for men of childbearing age after the last dose of cyclophosphamide
Exclusion Criteria:
- History of Cancer in the last 5 years
- Uncontrolled infection: Seropositivity for HIV or HTLV-1 or active hepatitis B or C defined by a positive PCR HBV or HCV and hepatic cytolysis due to HBV
- Uncontrolled coronary insufficiency, recent myocardial infarction <6 month, current manifestations of heart failure, uncontrolled cardiac rhythm disorders, ventricular ejection fraction <50%
- Pulmonary failure with DLCO<50%
- Addition of immunosuppressant treatment for GVHD prophylaxis (except immunosuppressant allowed per protocol)
- Renal failure with creatinine clearance <50ml / min
- Pregnancy (β-HCG positive) or breast-feeding
- Any debilitating medical or psychiatric illness which would preclude the realization of the SCT or the understanding of the protocol
- Under protection by law (tutorship or curatorship)
- Unwilling or unable to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: maximum tolerated dose
|
cellular therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose
Time Frame: 7 days
|
The maximum tolerated dose (MTD) will be defined by the highest dose (highest level) where no patient out of 3, or only 1 patient out of 6 presents with dose-limiting toxicity (DLT). The occurrence, within 7 days following one of the three injections, of any adverse event (AE) reasonably related to the injection of CSM-GW grade 3 to 5 according to the NCI-CTCAE classification version 5.0, or part of the "Important Medical Event list", or having a severity criterion The maximum tolerated dose (MTD) will be defined by the highest dose (highest level) where no patient out of 3, or only 1 patient out of 6 presents with dose-limiting toxicity (DLT). The occurrence, within 7 days following one of the three injections, of any adverse event (AE) reasonably related to the injection of CSM-GW grade 3 to 5 according to the NCI-CTCAE classification version 5.0, or part of the "Important Medical Event list", or having a severity criterion |
7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
acute and chronic GVHD incidence
Time Frame: 12 months
|
12 months
|
toxicity-related mortality (TRM)
Time Frame: 12 months
|
12 months
|
relapse incidence (RI)
Time Frame: 12 months
|
12 months
|
overall surival (OS)
Time Frame: 12 months
|
12 months
|
GvHD and relapse free survival (GRFS)
Time Frame: 12 months
|
12 months
|
poor graft function
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-504268-40-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft Failure
-
Masonic Cancer Center, University of MinnesotaRecruitingPrimary Graft Failure | Secondary Graft FailureUnited States
-
Swedish Orphan BiovitrumPRA Health Sciences; Cromsource; BioMérieux; Q2 Solutions; Cytel Inc.; ABF Pharmaceutical...Terminated
-
Swedish Orphan BiovitrumPRA Health Sciences; BioMérieux; Cytel Inc.TerminatedGraft FailureItaly, Belgium, United Kingdom, France, Germany, Netherlands
-
Baylor College of MedicineThe Methodist Hospital Research InstituteTerminated
-
Colorado Blood Cancer InstituteUnknown
-
Centre hospitalier de l'Université de Montréal...Centre de Recherche du Centre Hospitalier de l'Université de MontréalUnknownGraft Failure | Complications Due to Coronary Artery Bypass GraftCanada
-
University of OklahomaUniversity of Michigan; Emory UniversityRecruitingPrimary Graft FailureUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownLiver Transplantation | Graft FailureFrance
-
University Hospital, ToulouseRecruitingKidney Transplantation | Graft FailureFrance
-
Hospital do Rim e HipertensãoCompletedRenal Transplant Graft Failure
Clinical Trials on WJ-MSC infusion
-
Navy General Hospital, BeijingGeneral Hospital of Chinese Armed Police Forces; Chinese PLA General Hospital; First People's Hospital of FoshanCompletedST-Elevation Myocardial InfarctionChina
-
Banc de Sang i TeixitsCompletedCOVID-19 | SARS-CoV 2 | Adult Respiratory Distress SyndromeSpain
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruiting
-
McGill University Health Centre/Research Institute...Terminated
-
Banc de Sang i TeixitsComplexo Hospitalario Universitario de A Coruña; Institut Guttmann; Academic...CompletedSpinal Cord Injury CervicalSpain
-
Asia Stem Cell Regenerative Pharmaceutical Co.,...Recruiting
-
Joanne Kurtzberg, MDThe Marcus FoundationCompletedAutism Spectrum Disorder | Autism | ASDUnited States
-
Duke UniversityThe Marcus FoundationCompletedAutism Spectrum DisorderUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedDiscordant Immunological Response in HIV Infected SubjectsSpain
-
Joanne Kurtzberg, MDDuke Clinical and Translational Science Institute (CTSI), part of the NIH...CompletedModerate to Severe Hypoxic-ischemic EncephalopathyUnited States